体部立体定向放射治疗在结直肠癌肝转移中的进展

摘要/Abstract

摘要： 体部立体定向放射治疗（SBRT）是结直肠癌肝转移（CRLM）重要的局部治疗手段,在局部治疗手段中,需强调手术、热消融、SBRT优势互补的重要性。本文综述近年来精准SBRT的疗效与不良反应,并讨论影响肝转移SBRT疗效的主要因素,强调肝脏运动管理及影像引导技术对肿瘤控制的重要性;同时还详细阐述质子、重离子治疗在CRLM治疗中的研究进展。

关键词: 结直肠癌肝转移, 体部立体定向放射治疗, 疗效, 影响因素, 运动管理

Abstract: Stereotactic body radiotherapy(SBRT) serves as a vital local therapeutic modality for colorectal cancer liver metastases (CRLM). Among local therapeutic modalities, it highlights the significance of complementary advantages among surgical resection, thermal ablation and SBRT. This article reviews the efficacy and adverse events of high-quality SBRT reported in recent years, discusses the major factors governing the therapeutic outcomes of SBRT for liver metastases, and underscores the critical role of liver motion management and image-guided techniques in local tumor control. It also elaborates on the advances of proton and heavy-ion radiotherapy in the management of CRLM.

Key words: Colorectal cancer liver metastases, Stereotactic body radiotherapy, Efficacy, Risk factor, Liver motion management

王洪智, 董德左, 郑宣, 王维虎. 体部立体定向放射治疗在结直肠癌肝转移中的进展[J]. 肝癌电子杂志, 2026, 13(3): 34-39.

Wang Hongzhi, Dong Dezuo, Zheng Xuan, Wang Weihu. Advances in the application of stereotactic body radiotherapy for colorectal cancer liver metastases[J]. Electronic Journal of Liver Tumor, 2026, 13(3): 34-39.

参考文献

[1] 郑荣寿,陈茹,韩冰峰,等.2022年中国恶性肿瘤流行情况分析[J]. 中华肿瘤杂志,2024,46(3):221-231.
[2] Klement RJ, Guckenberger M, Alheid H, et al.Stereotactic body radiotherapy for oligo-metastatic liver disease - Influence of pre-treatment chemotherapy and histology on local tumor control[J]. Radiother Oncol, 2017, 123(2): 227-233.
[3] Rodríguez MRC, Zhao XC, Hernando O, et al.SBRT-SG-01: final results of a prospective multicenter study on stereotactic body radiotherapy for liver metastases[J]. Clin Transl Oncol, 2024, 26(7): 1790-1797.
[4] Rusthoven KE, Kavanagh BD, Cardenes H, et al.Multi-institutional phase Ⅰ/Ⅱ trial of stereotactic body radiation therapy for liver metastases[J]. J Clin Oncol, 2009, 27(10): 1572-1578.
[5] Romero AM, Schillemans W, van Os R, et al. The dutch-belgian registry of stereotactic body radiation therapy for liver metastases: clinical outcomes of 515 patients and 668 metastases[J]. Int J Radiat Oncol Biol Phys, 2021, 109(5): 1377-1386.
[6] Vautravers-Dewas C, Dewas S, Bonodeau F, et al.Image-guided robotic stereotactic body radiation therapy for liver metastases: is there a dose response relationship?[J]. Int J Radiat Oncol Biol Phys, 2011, 81(3): e39-e47.
[7] Scorsetti M, Comito T, Tozzi A, et al.Final results of a phaseⅡ trial for stereotactic body radiation therapy for patients with inoperable liver metastases from colorectal cancer[J]. J Cancer Res Clin Oncol, 2015, 141(3): 543-553.
[8] Mahadevan A, Blanck O, Lanciano R, et al.Stereotactic body radiotherapy (SBRT) for liver metastasis - clinical outcomes from the international multi-institutional RSSearch® patient registry[J]. Radiat Oncol, 2018, 13(1): 26.
[9] Folkert MR, Meyer JJ, Aguilera TA, et al.Long-term results of a phase 1 dose-escalation trial and subsequent institutional experience of single-fraction stereotactic ablative radiation therapy for liver metastases[J]. Int J Radiat Oncol Biol Phys, 2021, 109(5): 1387-1395.
[10] Stera S, Miebach G, Buergy D, et al.Liver SBRT with active motion-compensation results in excellent local control for liver oligometastases: an outcome analysis of a pooled multi-platform patient cohort[J]. Radiother Oncol, 2021, 158: 230-236.
[11] Wang H, Zheng X, Sun J, et al.4D-MRI assisted stereotactic body radiation therapy for unresectable colorectal cancer liver metastases[J]. Clin Transl Radiat Oncol, 2024, 45: 100714.
[12] Wei AC, Greig PD, Grant D, et al.Survival after hepatic resection for colorectal metastases: a 10-year experience[J]. Ann Surg Oncol, 2006, 13(5): 668-676.
[13] Solbiati L, Livraghi T, Goldberg SN, et al.Percutaneous radio-frequency ablation of hepatic metastases from colorectal cancer: long-term results in 117 patients[J]. Radiology, 2001, 221(1): 159-166.
[14] Rhaiem R, Kianmanesh R, Minon M, et al.Microwave thermoablation of colorectal liver metastases close to large hepatic vessels under pringle maneuver minimizes the "Heat Sink Effect"[J]. World J Surg, 2020, 44(5): 1595-1603.
[15] Jackson WC, Tao Y, Mendiratta-Lala M, et al.Comparison of stereotactic body radiation therapy and radiofrequency ablation in the treatment of intrahepatic metastases[J]. Int J Radiat Oncol Biol Phys, 2018, 100(4): 950-958.
[16] Yu J, Kim DH, Lee J, et al.Radiofrequency ablation versus stereotactic body radiation therapy in the treatment of colorectal cancer liver metastases[J]. Cancer Res Treat, 2022, 54(3): 850-859.
[17] Franzese C, Comito T, Clerici E, et al.Liver metastases from colorectal cancer: propensity score-based comparison of stereotactic body radiation therapy vs. microwave ablation[J]. J Cancer Res Clin Oncol, 2018, 144(9): 1777-1783.
[18] Rim CH, Lee JS, Kim SY, et al.Comparison of radiofrequency ablation and ablative external radiotherapy for the treatment of intrahepatic malignancies: a hybrid Meta-analysis[J]. JHEP Rep, 2023, 5(1): 100594.
[19] Lee J, Shin IS, Yoon WS, et al.Comparisons between radiofrequency ablation and stereotactic body radiotherapy for liver malignancies: Meta-analyses and a systematic review[J]. Radiother Oncol, 2020, 145: 63-70.
[20] Joo JH, Park JH, KimJC, et al. Local control outcomes using stereotactic body radiation therapy for liver metastases from colorectal cancer[J]. Int J Radiat Oncol Biol Phys, 2017, 99(4): 876-883.
[21] Flamarique S, Campo M, Asín G, et al.Stereotactic body radiation therapy for liver metastasis from colorectal cancer: size matters[J]. Clin Transl Oncol, 2020, 22(12): 2350-2356.
[22] Mayinger M, Ludwig R, Christ SM, et al.Benefit of replanning in MR-guided online adaptive radiation therapy in the treatment of liver metastasis[J]. Radiat Oncol, 2021, 16(1): 84.
[23] Jethwa KR, Jang S, Mullikin TC, et al.Association of tumor genomic factors and efficacy for metastasis-directed stereotactic body radiotherapy for oligometastatic colorectal cancer[J]. Radiother Oncol, 2020, 146: 29-36.
[24] Hong TS, Wo JY, Borger DR, et al. PhaseⅡ study of proton-based stereotactic body radiation therapy for liver metastases: importance of tumor genotype[J]. J Natl Cancer Inst, 2017, 109(9): djx031.
[25] Kim K, Yu J Ⅱ, Park HC, et al.A phase II trial of hypofractionated high-dose proton beam therapy for unresectable liver metastases[J]. Radiother Oncol, 2022, 176: 9-16.
[26] Coffma AR, Sufficool DC, Kang JI, et al.Proton stereotactic body radiation therapy for liver metastases-results of 5-year experience for 81 hepatic lesions[J]. J Gastrointest Oncol, 2021, 12(4): 1753-1760.
[27] Shyllon S, Penfold S, Dalfsen R, et al.Dosimetric comparison of proton therapy and CyberKnife in stereotactic body radiation therapy for liver cancers[J]. Phys Eng Sci Med, 2024, 47(3): 1203-1212.
[28] Shiba S, Wakatsuki M, Toyama S, et al.Carbon-ion radiotherapy for oligometastatic liver disease: a national multicentric study by the Japan Carbon-Ion Radiation Oncology Study Group (J-CROS)[J]. Cancer Sci, 2023, 114(9): 3679-3686.